Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema: An autopsy report
- PMID: 38045178
- PMCID: PMC10692797
- DOI: 10.1016/j.heliyon.2023.e22221
Coronavirus disease 2019 in a patient with pulmonary fibrosis and emphysema: An autopsy report
Abstract
Various diseases (e.g., hypertension and diabetes) are risk factors for the exacerbation of coronavirus 2019 (COVID-19). Patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) tend to develop severe COVID-19. Patients with severe COVID-19 present with acute respiratory distress syndrome (ARDS), and many COVID-19-related ARDS survivors eventually develop fibrosis. However, the appropriate management of patients with COVID-19 and ILD and post-COVID-19 ILD remains unclear. Thus, a better understanding of the pathology that exacerbates COVID-19 in patients with ILD is needed. We report the autopsy results of a patient with COVID-19 and combined pulmonary fibrosis and emphysema, whose lung organization and fibrosis progressed after the acute phase of infection. Histopathological findings suggest that fatal pulmonary fibrosis persists after the negative conversion of SARS-CoV-2. Elucidating the cause of death by autopsy may help determine therapeutic strategies in patients with COVID-19 and ILD. Vaccination and early administration of anti-inflammatory drugs or antifibrotic agents may be crucial for preventing disease progression and fatal lung fibrosis. This report aims to clarify the histopathological features of COVID-19 in patients with ILD via autopsy and discuss treatment strategies.
Keywords: Acute respiratory distress syndrome; Autopsy; COVID-19; Interstitial lung disease; SARS-CoV-2.
© 2023 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




Similar articles
-
Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD).Front Immunol. 2020 Oct 2;11:587517. doi: 10.3389/fimmu.2020.587517. eCollection 2020. Front Immunol. 2020. PMID: 33123171 Free PMC article.
-
Post-COVID lung fibrosis: The tsunami that will follow the earthquake.Lung India. 2021 Mar;38(Supplement):S41-S47. doi: 10.4103/lungindia.lungindia_818_20. Lung India. 2021. PMID: 33686978 Free PMC article. Review.
-
Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia.Expert Rev Clin Immunol. 2020 Aug;16(8):751-770. doi: 10.1080/1744666X.2020.1803064. Epub 2020 Oct 3. Expert Rev Clin Immunol. 2020. PMID: 32722946 Free PMC article.
-
Combination of acute exacerbation of idiopathic nonspecific interstitial pneumonia and pulmonary embolism after booster anti-COVID-19 vaccination.Respir Med Case Rep. 2022 May 24;38:101674. doi: 10.1016/j.rmcr.2022.101674. eCollection 2022. Respir Med Case Rep. 2022. PMID: 35637916 Free PMC article.
-
Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?Chin Med J Pulm Crit Care Med. 2023 Jun;1(2):77-83. doi: 10.1016/j.pccm.2022.12.002. Epub 2023 Jan 23. Chin Med J Pulm Crit Care Med. 2023. PMID: 37388822 Free PMC article. Review.
References
-
- World Health Organization Novel coronavirus situation report 2019-nCoV; 1. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous